“Biomarkers for Evaluation Spine Treatments (BEST)” is a clinical trial sponsored by NIAMS as a part of NIH HEAL Initiative’s Back Pain Consortium (BACPAC) Research Program, which is a translational, patient-centered effort to address the need for effective and personalized therapies for chronic low back pain (cLBP). The University of Washington is 1 of 12 institutions collaborating on this project. The BEST Trial extends this effort, informing a precision medicine approach to the treatment of cLBP by estimating an algorithm for optimally assigning interventional treatments based on the cLBP patient’s phenotypic markers and response to the treatments being evaluated: Evidence-based Exercise and Manual Therapy (EBEM), Duloxetine, Acceptance and Commitment Therapy (ACT), and Enhanced Self-Care (ESC).
Study Website: www.besttrial.org
Clinicaltrials.gov: https://clinicaltrials.gov/study/NCT05396014